Filgrastim and pegfilgrastim are marketed by Amgen in the United States and Europe under the trade names Neupogen® and Neulasta®, respectively. Since 1989, Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, a joint venture between Amgen and Japan’s Kirin Holdings, in Eastern Europe, Latin America, Asia, the Middle East, and Africa.
In those regions of the world, filgrastim and pegfilgrastim generated a combined approximately $200 million in sales last year. Roche had not disclosed sales for either drug last year or earlier this year.
The drugs are designed to reduce the risk of infection in patients receiving chemotherapy by boosting white blood cell counts.
Japan’s Kyowa Hakko Kirin will continue to retain product rights and to market filgrastim and pegfilgrastim in parts of Asia, including China and Japan.
- Amgen (AMGN) to Acquire Certain Filgrastim, Pegfilgrastim Assets from Roche (RHHBY) (streetinsider.com)
- Alternative to Amgen’s Neupogen Ready to Launch (arianaleilani.wordpress.com)
- Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets (biomedreports.com)
- Alternative to Amgen’s Neupogen Ready to Launch (arianaleilaninews.wordpress.com)
- Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets (markets.financialcontent.com)